Quantcast

Latest CorMedix Inc. Stories

2014-06-23 16:25:24

BRIDGEWATER, N.J., June 23, 2014 /PRNewswire/ -- CorMedix Inc. (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal and infectious disease, today announced the progress of on-going discussions with the U.S. Food and Drug Administration for a planned pivotal Phase 3 randomized controlled trial ("RCT") for Neutrolin® for use in hemodialysis patients with a central venous catheter....

2014-05-23 16:24:01

BRIDGEWATER, N.J., May 23, 2014 /PRNewswire/ -- CorMedix Inc. ("CorMedix") (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal disease and infectious disease, announces the receipt of a notice indicating that CorMedix did not meet certain of the NYSE MKT LLC's (the "NYSE MKT") continued listing standards as set forth in the NYSE MKT Company Guide ("Company Guide"). On May 19, 2014,...

2014-05-13 20:23:11

Host Conference Call at 9 am on Friday, May 16, 2014 BRIDGEWATER, N.J., May 13, 2014 /PRNewswire/ -- CorMedix Inc. ("CorMedix") (NYSE MKT: CRMD), a specialty pharmaceutical company focused on developing and commercializing therapeutic products for the treatment of infectious diseases in both acute and chronic care settings, today announced that a conference call will be held on Friday, May 16, 2014 at 9:00 a.m. ET to discuss the Company's first quarter 2014 results. Randy...

2014-04-07 08:31:14

BRIDGEWATER, N.J., April 7, 2014 /PRNewswire/ -- CorMedix Inc. (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal and infectious disease, today announced the appointment of three new board members. "We are very pleased to welcome Cora M. Tellez, Taunia S. Markvicka, and Michael W. George to the CorMedix team. The addition of these highly accomplished industry veterans represents...

2014-03-27 20:21:45

BRIDGEWATER, N.J., March 27, 2014 /PRNewswire/ -- CorMedix Inc. ("CorMedix") (NYSE MKT: CRMD), a specialty pharmaceutical company focused on developing and commercializing therapeutic products for the treatment of infectious diseases in both acute and chronic care settings, today announced that it will report 2013 financial results on Monday, March 31, 2014. The Company's Chief Executive Officer, Randy Milby, will be hosting a conference call on Tuesday, April 1, 2014 at 9:00 a.m. ET...

2014-03-10 16:32:59

- Company to present at 26th Annual ROTH Conference BRIDGEWATER, N.J., March 10, 2014 /PRNewswire/ -- CorMedix Inc. (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal and infectious disease, announced today that it has closed its previously announced registered direct offering of common stock and warrant units for gross proceeds to the Company of $7.4 million. Roth Capital...

2014-03-05 00:21:04

BRIDGEWATER, N.J., March 4, 2014 /PRNewswire/ -- CorMedix Inc. (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal and infectious disease, announced today that it entered into agreements with investors for a registered direct offering of 2.96 million units at the price of $2.50 per unit resulting in gross proceeds to the Company of $7.4 million. Each unit consists of one share of...

2014-01-13 08:29:03

Company Establishes Sales and Marketing Oversight Committee for Neutrolin Commercialization BRIDGEWATER, N.J., Jan. 13, 2014 /PRNewswire/ -- CorMedix Inc. (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardio-renal and infectious disease, today announced the establishment of letters of intent for the importation, sales, marketing and distribution of the Neutrolin catheter lock solution with...

2014-01-10 08:24:08

BRIDGEWATER, N.J., Jan. 10, 2014 /PRNewswire/ -- CorMedix Inc. (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardio-renal and infectious disease, today announced that the European Patent Office ("EPO") has granted a European patent for a low heparin catheter lock solution for maintaining patency and preventing infection in a hemodialysis catheter (sometimes referred to as "the Prosl...

2014-01-08 08:29:44

BRIDGEWATER, N.J., Jan. 8, 2014 /PRNewswire/ --- CorMedix Inc. (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal and infectious disease, today announced that it has entered into securities purchase agreements with investors pursuant to which it has agreed to sell 200,000 shares of Series C-3 Non-Voting Convertible preferred stock and a warrant to purchase up to 1,000,000 shares of common...


Word of the Day
penuche
  • A fudgelike confection of brown sugar, cream or milk, and chopped nuts.
'Penuche' is a variant of 'panocha,' a coarse grade of sugar made in Mexico. 'Panocha' probably comes from the Spanish 'panoja, panocha,' ear of grain.
Related